Skip to main content
Current Pharmaceutical Design publishes timely in-depth reviews covering all aspects of current research in rational drug design. Each issue is devoted to a single major therapeutic area. A Guest Editor who is an acknowledged authority in a therapeutic field has solicits for each issue comprehensive and timely reviews from leading researchers in the pharmaceutical industry and academia.

Each thematic issue of Current Pharmaceutical Design covers all subject areas of major importance to modern drug design, including: medicinal chemistry, pharmacology, drug targets and disease mechanism.

Publisher: Bentham Science Publishers

More about this publication?
Volume 15, Number 4, 2009

Articles

Favourites:
ADD

The Discovery of Antiangiogenic Molecules: A Historical Review
pp. 345-352(8)
Author: Ribatti, Domenico

Favourites:
ADD

Encountering and Advancing Through Antiangiogenesis Therapy for Gliomas
pp. 353-364(12)
Authors: Martin, Vanesa; Liu, Dan; Gomez-Manzano, Candelaria

Favourites:
ADD

Regulation of Angiogenesis by Macrophages, Dendritic Cells, and Circulating Myelomonocytic Cells
pp. 365-379(15)
Authors: (David) Dong, Zhao M.; Aplin, Alfred C.; Nicosia, Roberto F.

Favourites:
ADD

PI-3 Kinase-PTEN Signaling Node: An Intercept Point for the Control of Angiogenesis
pp. 380-388(9)
Authors: Castellino, R. C.; Muh, C. R.; Durden, D. L.

Favourites:
ADD

Angiogenic and Vascular Modulation by Extracellular Matrix Cleavage Products
pp. 389-410(22)
Authors: Suhr, Frank; Brixius, Klara; Bloch, Wilhelm

Favourites:
ADD
Favourites:
ADD
Favourites:
ADD

Apoptosis Pathways and Neuroblastoma Therapy
pp. 430-435(6)
Author: Fulda, S.

Favourites:
ADD

Targeting Histone Deacetylases in Neuroblastoma
pp. 436-447(12)
Authors: Witt, O.; Deubzer, H. E.; Lodrini, M.; Milde, T.; Oehme, I.

Favourites:
ADD

Genome and Transcriptome Analysis of Neuroblastoma Advanced Diagnosis from Innovative Therapies
pp. 448-455(8)
Authors: Coco, S.; Tonini, G. P.; Stigliani, S.; Scaruffi, P.

Favourites:
ADD
Favourites:
ADD

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content